Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SangStat Medical Corp.

Division of Sanofi
www.sangstat.com

Latest From SangStat Medical Corp.

Cambridge Antibody: Time to Transform

Critics charge that Cambridge Antibody's lack of involvement to date in the clinical fate of its antibodies has caused it to stagnate and opened up a significant gap in the firm's pipeline. The recent renegotiation of its anti-TGF-beta deal with Genzyme, however, demonstrates CAT's willingness to take increased risks, and that it recognizes the need to take a greater stake in the development of its own product candidates. Once CAT begins to buy in the products necessary to invigorate its pipeline it will be easier to look past the firm's lackluster dealmaking and a royalty dispute with Abbott over Humira. After all, CAT has an industry-leading technology platform and an ample cash-pile, and there have been recent signs of life in the antibody licensing market.
BioPharmaceutical Europe

Renewing Novartis

Novartis has unexpectedly re-created itself with a back-to-basics, centrally-driven marketing effort accomplished by an almost entirely new senior marketing group. The transformation has been expensive and the company used a significant portion of the cost savings from the Ciba/Sandoz merger which created Novartis to finance increased marketing and Phase IV clinical development of key current products, as well as larger and more numerous trials for major development candidates, rather than simply to drive short-term earnings increases. The company is now attempting to take the centralization still further into global management. By creating global brands, it feels it can more efficiently capture leading share of voice and thus, at lower cost and with a smaller total sales force, create worldwide brand leaders.
BioPharmaceutical Strategy

Marketing Specialty Drugs Online

Three companies, SangStat Medical Corp., Chronimed Inc., and Bergen Brunswig Corp., are bringing their specialty pharmacy businesses online. SangStat's offering, TransplantRx.com, will probably be spun-off into a separate business.
BioPharmaceutical Business Strategies

Innogenetics on its Own

Innogenetics, like many biotech companies, has built a diagnostics business in order to capture short-term revenues. But it got squeezed by industry consolidation and its response is an aggressive and expensive strategy to increase its emphasis on high-margin, novel tests, which it will use to fund conversion to a direct sales and marketing network in major markets.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders > Organ Transplantation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sanofi
  • Senior Management
  • Richard Murdock, Pres. & CEO
    Stephen G Dance, SVP, Fin.
  • Contact Info
  • SangStat Medical Corp.
    Phone: (510) 789-4300
    6300 Dumbarton Cir.
    Freemont, CA 94555
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register